A different inhibitor is required for overcoming entecavir resistance: a comparison of four rescue therapies in a retrospective study.

Guosheng YuanChengguang HuYuchen ZhouJunwei LiuHuaping HuangYuan LiDinghua YangFuyuan ZhouYong-Yuan ZhangYuanping Zhou

Published in: British journal of clinical pharmacology (2017)

TDF monotherapy appeared to deliver the highest undetectable HBV DNA rate in patients with ETV resistance, and ADV plus ETV combination therapy could be another choice for patients with financial restraint.

Keyphrases

combination therapy
acute lymphoblastic leukemia
hepatitis b virus
circulating tumor
cell free
healthcare
randomized controlled trial
open label
health insurance
double blind